Interleukin-5, Eosinophils, and Disease
By Colin J. Sanderson OSINOPHIL production can be induced in vitro by E interleukin-3 (IL-3), granulocyte-macrophage colonystimulating factor (GM-CSF), and IL-5. Both IL-3 and GM-CSF have activities on other hemopoietic lineages, whereas IL-5 is specific for the eosinophil/basophil lineage. The activity of IL-5 on basophils has been reviewed recently' and will not be discussed here. There is now good evidence that IL-5 is the major, and possibly the only, cytokine involved in the production of specific eosinophilia. Classically eosinophilia is observed in a restricted number of diseases, most notably helminth infections and allergic diseases. However, although the increase in eosinophil numbers is less spectacular, there is increasing evidence for an involvement of eosinophils in a wider spectrum of diseases.
A study of experimental infection of volunteers by the hookworm Necator americanus gave clear evidence for an increase in eosinophils with no significant increase in other blood leucocytes,2 and infection of mice with the cestode Mesocestoides Corti causes a massive increase in blood and peritoneal eosinophils with little effect on the number of ne~trophils.~ This biologic specificity, the relatively restricted disease profile of eosinophilia, and the requirement for a functional T-lymphocyte ~y s t e m~-~ suggested that the control of eosinophilia must be part of the immune response and based on a subset of T celk7
Eosinophils are cytotoxic cells capable of killing helminths, parasitic protozoa, chicken erythrocytes, and tumor cells in vitro. For more general reviews and background see Spry, 8 Dexter et a1, 9 Thompson,'O and Smith and Cook.ll Time-lapse cinematography has shown that eosinophils phagocytose and regurgitate red blood cells very rapidly. This is in contrast to neutrophils and macrophages that retain them until they have been broken down.12 This explains why eosinophils appear to be less active in comparison to neutrophils in classical phagocytosis assays using yeast or bacteria. They do not retain the particles. It is unclear what this implies for the killing ability of the eosinophil, but it is possible that they are better adapted to attach to large parasites13 rather than to phagocytose small particles.
IL-5 STRUCTURE
IL-5 is unusual among the T-cell-produced cytokines in being a disulphide-linked homodimeric glycoprotein. It is highly homologous between species, as indicated by the high sequence homology between mouse and human 1L-5 and the cross-reactivity of the protein across a variety of mammalian species. Mature human IL-5 monomer comprises 115 amino acids (molecular weight [M,] of 12,000 and 24,000 for the dimer). The secreted material has an M, of 40,000 to 45,000, and thus nearly half the native material consists of carbohydrate, although this carbohydrate does not appear to be necessary for biologic activity in vitro.14 Studies with mouse IL-5 indicate that the monomer has no biologic activity and has no inhibitory activity, suggesting that they do not form high-affinity interactions with the IL-5 receptor (IL-5R).IS The dimer exists in an antiparallel (head to tail) c o n f i g u r a t i~n .~~-~~
INTERACTION WITH IL-5 R
Binding studies of IL-3, IL-5, and GM-CSF to human eosinophils showed cross-inhibition, suggesting some common components in the receptors for each cytokine.18J9 Murine eosinophils have been calculated to express approximately 50 high-affinity receptors for IL-5 (kd in the range of 4 to 6 x lo-'' mol/L) and approximately 5,000 lowaffinity rceptors (kd in the range of 0.3 to 2 x mol/L).20 Initial work on the human receptor used a clone of the human promyelocytic leukemia cell line HL-60.*l These cells express only a single population of high-affinity IL-5 binding sites. Similarly, only a single high-affinity receptor population (kd range, 3 to 6 x lo-" mol/L) has been identified on human eosinophil^.^^-^^ Recent work has shown that each of these human receptors consists of (at least) an a-and a P-chain. The a-chains are unique to each cytokine and form a group of homologous glycoproteins within the hematopoietin receptor super family.25 The a-chain forms a low-affinity bond with the analogous cytokine. The P-chain is common to all three receptors and in combination with the a-chain forms the high-affinity r e c e p t~r .~~.~~ It seems likely that the cross inhibition exhibited within the group is due to limiting numbers of p-chains.28
Structure-function studies exploiting human-mouse hybrid molecules and the distinct cross-species reactivities displayed by these molecules identified an important role for the C-terminal region in the determination of both biologic activity and receptor binding. 29, 30 There is an area of sequence similarity, determined using Dayhoff mutation indices, at the C-terminal region of a number of different cytokines, including IL-5.31 The head-to-tail arrangement of the dimer and the importance of the C-terminal regions of the molecule imply that the configuration of the IL-5 molecule probably forms two receptor binding sites.
Experiments with GM-CSF suggest that the p-chain may bind in the region of residue 2132 and a series of mousehuman GM-CSF hybrids identified residue 20 as important in the interaction with the p-chain. Furthermore, a hybrid in which the N-terminal region of GM-CSF was substituted by the analogous region from IL-5 showed strong biologic activity. This very elegant approach showed that IL-5 uses the same P-receptor subunit as GM-CSF, and implies an interaction between the p-chain and the N-terminal region of the cytokine molecule.33
The mouse receptors show some differences with the human counterparts. Firstly, there is no demonstrable cross-inhibition, possibly indicating that the p-chains are present in excess. Secondly, the receptors show both highand low-affinity binding, whereas those in humans show a single class of high-affinity binding. Thirdly, the counterpart of the human IL-3 a-chain has not been identified. A protein (AIC2A) binds to IL-3 with low affinity34 and is closely related to a protein (AIC2B) that is the P-chain for the IL-5R.3SJ6 However, expression of the two proteins (AIC2A) and AIC2B) does not reconstitute a high-affinity receptor for IL-3, and so the structure of the high-affinity IL3R is not yet clear. Finally, mouse B cells express IL-5R37-39 and the generation of IL-5-dependent murine pro-B-cell lines has greatly facilitated the characterization of IL-5R.37,40
An intriguing aspect of the cloning of the IL-5R was that the most abundant transcript encoded a soluble form of the receptor, lacking a transmembrane regi0n.2~9~~ This soluble form was inhibitory in an eosinophil differentiation assay with IL-5, raising the possibility that eosinophil production may be regulated by switching between a membrane-bound and a soluble form of the IL-5R.
CYTOKINE GENE CLUSTER
The genes encoding IL-3, IL-4, IL-5, and GM-CSF share certain structural features and form a cluster on chromosome 5 in human^^^,^^ and on chromosome 11 in the mouse.44 This finding suggests that they are members of a gene family and raises the possibility of common mechanisms in the control of expression. Studies with T-cell clones in vitro indicate that IL-4 and IL-5 are often coexpressed in clones designated Th2.45 However, anti-CD3 induces the expression of IL-4, IL-5, and GM-CSF messenger RNA (mRNA) in mouse T cells, whereas treatment with IL-2 induced IL-5 mRNA expression but did not induce detectable IL-4 or GM-CSF.& That eosinophilia can occur without increases in other leukocytes suggests an independent control for IL-5 expression, while the association between high levels of IgE antibody and eosinophilia suggests coordinate expression of IL-4 and IL-5 in these cases.
The molecular mechanism of the regulation of the genes in this cytokine gene cluster is not understood, but it appears likely that both common and independent control mechanisms exist between IL-5 expression and the expression of the other genes.
PRODUCTION OF EOSINOPHILS IN VITRO
The first studies on the production of eosinophils in vitro4' indicated that an eosinophil colony-stimulating activity was present in mouse spleen-conditioned medium. However, with mouse marrow the eosinophil colony assay has low sensitivity compared with simple liquid culture ~y s t e m s , 4~-~~ and it was the development of a liquid assay and quantification by assay for eosinophil peroxidase that led to the identification of a murine cytokine called eosinophil differentiation factor and subsequently termed IL-5.7,31,51,52 Although the difference is not so marked with human bone marrow cells, IL-5 performs poorly in colony assays compared with IL-3 and GM-CSF, whereas in liquid cultures the situation is reversed and IL-5 stimulates more eosinophil production than the other c y t o k i n e~.~~~~~,~~ Whereas IL-5 is specific for the production of eosinophils, both GM-CSF and IL-3 induce the production of neutrophils, macrophages, and e o~i n o p h i l s .~~~~~ A number of studies have suggested that IL-5 is a late-acting factor for eosinophil production. The transient production in vitro in both human and mouse culture systems suggests that IL-5 is incapable of stimulating the production of eosinophil precursor^.^,^^^^^,^^ Other studies have suggested a network of cytokines is involved in the production of eosinophil precursor^.^^^^^ Both IL-3 or GM-CSF can induce a significant increase in eosinophil precursors, as assessed by colony formation in semi-solid agar cultures with IL-5,58-60 which is consistent with the network hypothesis. However, a network involving cytokines with activities on other lineages is difficult to reconcile with the biologic specificity of eosinophilia.
IL-5 ACTIVITY IN VIVO
In contrast to studies in vitro, experiments in vivo clearly indicate the central role of IL-5 in eosinophilia and indicate that experiments in vitro may be misleading, possibly because the culture conditions do not accurately reproduce the microenvironment of the bone marrow.
The administration of anti-IL-5 antibody to mice infected with Nippostrongylus brasi1iensis:l Schistosoma mansoni,62 Heligmosomoides polygylu~,~~ or Strongyloides venezuelensis@ totally blocked the development of eosinophilia. These experiments show the essential role that IL-5 performs in the control of eosinophilia in such parasite infections. In addition, they show that the apparent redunFor personal use only. on October 30, 2017. by guest www.bloodjournal.org From dancy seen in vitro, in which both IL-3 and GM-CSF are also able to induce eosinophil production, does not operate in these infections.
Two types of experiments have shown that expression of the IL-5 gene in vivo is sufficient to induce eosinophilia. Firstly, mice carrying hematopoietic cells infected with a retrovirus carrying the IL-5 gene produced high-level eosinophilia for at least 12 months.65 There were excess numbers of eosinophils in the bone marrow, spleen, liver, lung, and gut.
Secondly, transgenic mice that express IL-5 by two different methods show long-lasting eosinophilia. Firstly, the IL-5 gene was ligated to the human CD2 locus control region (LCR) to give constitutive expression of IL-5 by all T cells. Secondly, the IL-5 cDNA was ligated to the mouse metallothionein promoter (MT-1) to give a low-level constitutive production of IL-5 from spleen, liver, kidney, and bone marrow.
Four lines of transgenic mice produced with the CD2-IL-5 construct all showed high-level eosinophil production proportional to the transgene copy number. These animals have detectable levels of IL-5 in the serum, and show a profound and lifelong eosinophilia, with large numbers of eosinophils in the blood, spleen, bone marrow, lung, and gut Of the two transgenic lines produced with the MT-1-IL-5 construct, one carried about five copies of the transgene and produced low and variable levels of eosinophils, but the other carried about 40 copies and gave high-level eosinophilia in the spleen, peritoneum, liver, and skeletal muscle.67
ACTIVITY OF IL-3 AND GM-CSF IN VIVO
To assess the relative importance of IL-5 in eosinophilia, it is important to understand the activities of IL-3 and GM-CSF that induce eosinophil production in vitro. Firstly, the dose required for optimum eosinophil production in vitro by IL-3 or GM-CSF is at least 10-fold higher than the dose required to induce neutrophillmacrophage production.68 Secondly, in assessing increases in eosinophils numbers, it is important to note that the number of eosinophils in normal animals is very low, and so even when the numerical increase is not large, it can appear large when expressed as a multiple. Clinical trials with IL-3 and GM-CSF have shown that they both stimulate the production of eosinophils, although the actual increase in eosinophils is relatively low compared with the effect on other lineage^.^^.^^ Results in experimental animals also indicate a low activity on eosinophils compared with other lineages. Injections of IL-3 into mice induced an increase of about 3 x lo6 eosinophils in the peritoneum compared with an increase of about 14 X lo6 macrophage^,^^ whereas GM-CSF induced about 4 x lo6 eosinophils compared with about 25 x lo6 macrophages.72
Mice reconstituted with bone marrow cells that express GM-CSF had very high levels of serum GM-CSF and high levels of neutrophils and macrophages. Although the number of eosinophils was increased ninefold over controls, this was a very small fraction of the total cell increase. 73 Similary, mice that express high levels of IL-3 had increased numbers of neutrophils, but the increase in eosinophils represented less than 5% of the total cells.74 Transgenic mice expressing GM-CSF developed a massive myeloid response, but eosinophils represented less than 5% of the total in one line and in another less than l%.75
As high levels of either IL-3 or GM-CSF result in relatively low production of eosinophils in vivo, it is unlikely that these cytokines play a significant role in eosinophilia under conditions in which their levels are low or undetectable, as occurs in most pathologic conditions.
EFFECT OF OVERPRODUCTION OF IL-5
Animals reconstituted with hematopoietic cells that constitutively express IL-3,74 GM-CSF,73 and IL-565 have been reported. The animals reconstituted with cells expressing IL-3 or GM-CSF survived only a few weeks due to massive tissue infiltration by myeloid cells. In contrast, the IL-5 mice developed eosinophilia but remained healthy.65 Similarly, despite the massive, life-long eosinophilia in both models of IL-5 transgenic mice, they remained apparently n~r m a l .~,~~ This finding is in contrast to transgenic mice expressing GM-CSF that develop a myeloid response resulting in blindness and a fatal syndrome of tissue damage. 76 These observations illustrate that increased numbers of eosinophils are not themselves harmful, or that a control mechanism exists to prevent the production of eosinophils to toxic levels.
Infection of the CD2-IL-5 transgenic mice with M Corti, itself a potent inducer of eosinophilia, increased serum IL-5 from about 40 U to over 1,000 U. However, the number of eosinophils in the blood, bone marrow, and spleen decreased during the period corresponding to high-level serum IL-5. This was shown to be due to a decrease in eosinophil precursors. This also suggests that some form of control is operating to prevent the overproduction of eosinophil^.^^
ASSOCIATION BETWEEN IL-5 AND EOSINOPHILIA
The development of eosinophilia in mice infected with T canis is accompanied by the appearance of IL-5 mRNA in the A comparison of the production of cytokines by normal individuals and by eosinophilic patients infected with the filarial parasite Loa loa gave interesting results. It was found that both groups produced similar levels of IL-3 and GM-CSF, but whereas the normals gave relatively little IL-5, the cells from infected patients produced high levels of IL-5.79
Significant levels of IL-5 were also detected in the serum of patients with idiopathic hypereosinophilia80 and in patients with the eosinophilic-myalgia syndrome resulting from the ingestion of L-tryptophane. 81 Patients with eosinophilia associated with Hodgkin's disease were found to have IL-5 mRNA in the tumor cells,82 and a patient with angiolymphoid hyperplasia with eosinophilia (Kimura's disease) was found to have constitutive expression of IL-5 mRNA in lymph node tissue. 83 Asthma is associated with an inflammatory reaction involving the infiltration of eosinophils, and in situ hybrid- 
EOSINOPHIL LOCALIZATION
Eosinophil infiltration of the tissues frequently occurs independently of other blood leukocytes. This suggests that a mechanism must exist for the specific extravasation of eosinophils. The different tissue distribution of eosinophils in the two transgenic systems (discussed above) probably results from the different tissue expression of IL-5. Using the MT-1 promoter, transgene expression was shown in the liver and skeletal muscle, and eosinophils were observed in these tissues. In contrast, the CD2-IL-5 mice with IL-5 expression in T cells did not have eosinophils in the liver or skeletal muscle. This suggests that eosinophils migrate into tissues in which IL-5 is expressed. While IL-5 is reported to be chemotactic for eosinophil^,^^^^^ the activity is relatively weak, and it is not clear what role that could play in vivo.
An alternative mechanism of extravasation of eosinophils is suggested by experiments in which IL-5 has been shown to upregulate adhesion molecules. Thus, it was shown that IL-5 increased the expression of the integrin CDllb on human eosinophil^,^^ and this increased expression was accompanied by an increased adhesion to endothelial cells.86 Adhesion was inhibited by antibody to CDllb or CD18 suggesting that the integrins are involved in eosinophil adhesion to endothelial cells.86 More recently, it has been shown that eosinophils can use the integrin very late antigen-4 (VLA-4) (CD49d/CD29) in adherence to endothelial cells. In this case, the ligand is vascular cell adhesion molecule-1 (VCAM-1). In contrast, neutrophils do not express VLA-4 and do not use this adherance me~hanism.~' While none of these adhesion molecules are restricted to eosinophils, these results suggest a possible pathway for the specific localization of eosinophils. The activation of T cells as part of the immune response in the tissues presumably leads to the production of IL-5 and one or more of the cytokines influencing endothelial cell expression of adhesion molecules. The IL-5 increases the expression of adhesion molecules on the circulating eosinophils. The total effect is to increase the adhesion of eosinophils to the vessel walls in the inflamed tissue. Clearly, the production of cytokines such as IL-3 and GM-CSF that upregulate adhesion molecules on monocytes and neutrophils would cause these cells to comigrate with the eosinophils.
The potential for blocking eosinophil adhesion as a therapeutic approach to asthma has been shown in a primate asthma model. It was first shown that antibody to intracellular adhesion molecule-1 (ICAM-1) inhibited the adhesion of eosinophils to endothelial cells in vitro. When the antibody was administered to the animals, eosinophil migration into the lung was decreased and the asthmatic reaction significantly reduced.88
EOSINOPHILS AND HELMINTHS
While the association between eosinophils and infections by helminths has been well documented, it has been more difficult to show that the eosinophils were involved in parasite rejection. The observations that eosinophils in vitro could kill schistosomula of Schistosoma mansoni l3 have been followed by many similar descriptions with different parasites. The association between eosinophilia and resistance to schistosomiasis in two studies in Africa remain the best evidence that eosinophils are involved in immunity to parasite^.^^^^ Bearing in mind the high conservation of the IL-5 sequence and the high exposure to parasites in nature, it is possible that resistance to parasitic infections has provided the selective pressure for the evolution of IL-5.
EOSINOPHILS AND ASTHMA
Although the potential role of the eosinophil in the production of tissue damage in asthma has been evolving for some years,91 the central role of the eosinophil as possibly the most important inflammatory cells in asthma is becoming more widely a~c e p t e d .~~-~~ Antigen challenge of asthmatic patients results in the accumulation of eosinophils in the and the number of eosinophils correlates with the severity of the late asthmatic reaction?6 The accumulation of eosinophils was found to be selective after specific allergen inhalation, because the numbers of macrophages, neutrophils, and lymphocytes were not significantly increased. Patients with a late response showed a significant increase in eosinophils by 4 hours with higher numbers at 24 hours.97 Experimental asthma in guinea pigs is accompanied by large numbers of eosinophils in the peribronchial vessels, the mucosa, and the airways.98 Similarly, inhalation of antigen in sensitized primates (Macacafasiculurk) resulted in a prolonged inflammatory reaction characterized by a large increase in bronchialveolar eosinophil^.^^ Evidence that eosinophils are producing tissue damage in the asthmatic lung is based on the demonstration of eosinophil major basic protein and eosinophil-derived neurotoxin, indicating degranulation at sites of injury. Furthermore, the concentrations of these toxic products in asthmatic sputum is similar to the concentrations that are cytotoxic in These types of data have caused a reappraisal of the etiology of the late-phase asthmatic reaction from a disease mediated by mast cells and IgE to a disease that is primarily a T-cell response (delayed-type hypersensitivity reaction) accompanied by e o~i n o p h i l i a .~~,~~.~~,~~~
EOSINOPHILS AND GRAFT REJECTION
Eosinophilia was noted 1 to 4 days before the development of inflammation after renal transplantation,lo2 and this was shown to be an adverse prognostic factor for graft s~r v i v a I .~~~J~ Eosinophils in liver grafts were reported to be a sensitive and specific indicator for acute rejection.105 Experimental lung allograft in the rat causes eosinophil For personal use only. on October 30, 2017 . by guest www.bloodjournal.org From infiltration, representing up to 20% of the cell infiltration 2 to 4 days after implantation.lM It is not clear from these observations whether the eosinophils are involved in graft rejection or whether they simply represent a marker for an active T-cell response.
EOSINOPHILS AND TUMORS
Approximately half of the patients receiving abdominal irradiation as curative therapy for tumors developed eosinophilia as a consequence of the irradiation. This was found to be an important prognostic factor, independent of other parameters indicative of cell-mediated immunity. Those who developed eosinophilia had double the median survival time of those who did
The presence of eosinophils in association with tumors has been noted for many years.8J08 In a histologic study of the cellular infiltration of tumors, it was observed that in oral, gastric, and breast carcinomas only a small proportion of cases had eosinophils and these occurred as an insignificant part of the infiltrate. However, in carcinoma of the cervix, eosinophils were observed in one-third of the cases (43 of 134) and there was a positive correlation between eosinophils and survival rates.lW In a study of 72 operable primary lung cancers, 37 (50%) showed a strong local infiltration of eosinophils. Follow-up studies indicated that this was associated with a good prognosis, while absence of eosinophils indicated a poor prognosis.l1° In a prospective study of 647 cases of gastric carcinoma in Japan, 157 (24%) showed eosinophil infiltration in the resected tumor. This was found to have a marked positive prognostic significance."' In a study of 67 patients with colonic carcinoma, 18-month survival was higher in the group with high eosinophil infiltration.lI2
In Hodgkin's disease, a selective blood eosinophilia, without a general leukocytosis, occurred in 95 of 1,260 cases (7.5%). This was associated with a clear selective advantage,lI3 and appears to be caused by IL-5 production by the tumor cells.82 An extensive deposition of eosinophil peroxidase in a proportion of biopsies indicated eosinophil degranulation and suggested a cytotoxic effect may be o~curring."~ An intriguing experimental system designed to assess the role of cytokines in tumor rejection uses tumor cells transfected with an expression vector containing the cDNA sequence of a cytokine. The tumor cells produce the cytokine constitutively. When tumor cells secreting IL-4115 or IL-2116 were introduced into mice, they were rejected faster than the parent tumor cells. In both cases the tumors were infiltrated with eosinophils, possibly (but not proven) because the animal's T cells were stimulated to produce Patients receiving IL-2 as an antitumor treatment frequently develop eosinophilia. This appears to be because IL-2 induces the production of IL-5 by T cells.l17 In view of the observations (discussed above) that eosinophils correlate with a positive prognosis, it may be useful to analyze the number and distribution of eosinophils for a correlation with the antitumor activity of IL-2.
IL-5.

CONCLUSION
Most cytokines appear to be pleitropic and as they have become more widely available the range of their biologic activities has increased. On the other hand, the availability of human IL-5 has narrowed our concepts of its biologic role. Mouse IL-5 has well-characterized activities on B cells in vitro and activities on T cells have been reported, but in humans IL-5 appears not to act on B cells1ls and no activities have been reported on T cells. Thus, in humans IL-5 activity appears to be restricted to the eosinophil/ basophil lineages.
Studies in vitro suggested that IL-5 was a late-acting factor in a cytokine network in which IL-3 and GM-CSF played a key role in controlling eosinophilia. However, the complete inhibition of eosinophil production by anti-IL-5 antibody and the development of eosinophilia in transgenic mice expressing only IL-5 suggests that studies in vitro may be misleading. Furthermore, the association of eosinophilia with the production of IL-5 in a wide spectrum of human eosinophilic diseases all indicate a unique role for IL-5 in the regulation of eosinophilia.
In view of the potential for eosinophils to cause tissue damage, it is interesting that constitutive expression of IL-5 in mice induced long-lasting eosinophilia without apparent ill effects. This suggests that additional factors, such as antibody-antigen complexes, are required to induce the cytotoxic effect of eosinophils. Expression of very high levels of IL-5 appears to suppress the production of eosinophils, possibly indicating some form of control to prevent their over production. The soluble IL-5R inhibits IL-5 activity, suggesting the possibility that high levels of IL-5 lead to expression of the soluble form (rather than the membrane form) of the IL-SR, thus regulating the production of eosinophils.
The unique role of IL-5 in the production, activation, and localization of eosinophils makes it a prime target for therapeutic intervention in asthma and other eosinophilic diseases. On the other hand, eosinophils have been shown to be a positive prognostic indicator in a variety of human tumors.
The studies of eosinophils in tumors do not directly implicate eosinophils as the effector cells in tumor rejection. However, they represent a remarkable positive prognostic indicator, and raise the possibility that manipulation of eosinophil numbers might be used in tumor therapy. Systemic administration of IL-5 may induce eosinophilia, but will not provide the eosinophil infiltration that will probably be necessary. A possible approach would be to use IL-5 to increase eosinophils in those patients known to have infiltrating eosinophils in their tumors. This would be based on the assumption that the tumors were producing the stimulus causing the eosinophils to localize. While experiments in animals suggest that eosinophil induction may not be harmful, this may not be an indicator of the effects in humans. It is possible that subclinical allergic disease may be exacerbated by an increase in eosinophils, and this provides a daunting barrier for the clinical application of IL-5. 
